key: cord-1020846-w0b14501
authors: Tieu, Alvin; Hu, Kevin; Gnyra, Catherine; Montroy, Joshua; Fergusson, Dean A.; Allan, David S.; Stewart, Duncan J.; Thébaud, Bernard; Lalu, Manoj M.
title: Mesenchymal stromal cell extracellular vesicles as therapy for acute and chronic respiratory diseases: A meta‐analysis
date: 2021-10-01
journal: J Extracell Vesicles
DOI: 10.1002/jev2.12141
sha: 06be76fe89482af7e99e5e2249ce989947ae5190
doc_id: 1020846
cord_uid: w0b14501

Preclinical studies suggest mesenchymal stromal cell extracellular vesicles (MSC‐EVs) reduce inflammation and improve organ function in lung diseases; however, an objective analysis of all available data is needed prior to translation. Using rigorous meta‐research methods, we determined the effectiveness of MSC‐EVs for preclinical respiratory diseases and identified experimental conditions that may further refine this therapy. A systematic search of MEDLINE/Embase identified 1167 records. After screening, 52 articles were included for data extraction and evaluated for risk of bias and quality of reporting in study design. A random effects meta‐analysis was conducted for acute lung injury (ALI; N = 23), bronchopulmonary dysplasia (BPD; N = 8) and pulmonary arterial hypertension (PAH; N = 7). Subgroup analyses identified EV methods/characteristics that may be associated with improved efficacy. Data is presented as standardized mean differences (SMD) or risk ratios (RR) with 95% confidence intervals (CI). For ALI, MSC‐EVs markedly reduced lung injury (SMD ‐4.33, CI ‐5.73 to ‐2.92), vascular permeability (SMD ‐2.43, CI ‐3.05 to ‐1.82), and mortality (RR 0.39, CI 0.22 to 0.68). Small EVs were more consistently effective than large EVs whereas no differences were observed between tissue sources, immunocompatibility or isolation techniques. For BPD, alveolarization was improved by MSC‐EVs (SMD ‐1.45, CI ‐2.08 to ‐0.82) with small EVs more consistently beneficial then small/large EVs. In PAH, right ventricular systolic pressure (SMD ‐4.16, CI ‐5.68 to ‐2.64) and hypertrophy (SMD ‐2.80, CI ‐3.68 to ‐1.91) were significantly attenuated by EVs. In BPD and PAH, EVs isolated by ultracentrifugation demonstrated therapeutic benefit whereas tangential flow filtration (N = 2) displayed minimal efficacy. Lastly, risk of bias and quality of reporting for experimental design were consistently unclear across all studies. Our findings demonstrate clear potential of MSC‐EVs to be developed as therapy for acute and chronic lung diseases. However, greater transparency in research design and direct comparisons of isolation technique and EV subtypes are needed to generate robust evidence to guide clinical translation. Protocol Registration: PROSPERO CRD42020145334

We included any in vivo animal models of respiratory disease or injury. Invertebrate animals, in vitro or ex vivo preclinical studies were excluded.

Studies must have administered MSC-EVs for inclusion. All animal or tissue source of MSCs were included. MSCs or EVs may have been pre-treated, co-treated or modified (e.g. gene transfection). All routes, doses, timing and frequency of administration were included. Studies may have administered EVs as xenogeneic, allogeneic or autologous products. Studies in which EVs were not derived from MSCs, or were not administered to animals directly, were excluded.

All comparators including (but not limited to) placebo, vehicle control, MSCs and/or fibroblasts were considered.

Primary, secondary and tertiary outcomes were selected for acute lung injury (ALI), bronchopulmonary dysplasia (BPD), and pulmonary arterial hypertension (PAH), the three most studied lung conditions for MSC-EV therapy. For lung conditions outside of ALI, BPD, and PAH, the primary and secondary outcomes reported in the articles were extracted for narrative synthesis. Studies in which outcomes did not assess EV efficacy (e.g. only the biodistribution of EVs was assessed) were excluded.

We included controlled interventional studies (randomized, pseudo-randomized, or non-randomized), while unpublished grey literature, abstracts, review articles, editorials, commentaries, and letters were excluded. Studies were not excluded based on language or publication date.

A systematic search of Ovid MEDLINE, Ovid MEDLINE In-Process & Other Non-Indexed Citations, and Embase Classic + Embase was conducted until March 6, 2019 using a broad search strategy for any in vivo study investigating MSC-EVs. To update our study, an additional search was conducted on 4 August, 2020 with lung disease filters. Both search strategies (Supplemental File 2) were designed with the help of an information specialist and assessed by a second information specialist through the Peer Review of Electronic Search Strategies (PRESS) (McGowan et al., 2016) . The search strategies were modified according to database and used controlled vocabulary, MeSH terms (e.g. mesenchymal stem cells, mesenchymal stromal cells, extracellular vesicles, exosomes, microvesicles), abbreviations (e.g. MSCs, EVs, MVs), and filters for preclinical animal models. No restrictions were applied for publication date.

Titles and abstracts were independently screened in duplicate (AT, MS, CG and/or KH) using the Distiller Systematic Review Software (DistillerSR, Evidence Partners, Ottawa, Canada). A calibration test using 10 studies was performed before beginning the formal screening process to ensure high inter-rater correlation (kappa 0.8). Titles and abstracts that met criteria or that could not be excluded with certainty moved on to full-text screening. Following a calibration test involving 10 studies, two reviewers (AT, MS, CG and/or KH) independently reviewed the full-text articles. Reasons for exclusion were recorded at this stage. Disagreements between reviewers were resolved through discussion. The selection process is presented in a PRISMA flow diagram ( Figure 1 ). Standardized data extraction forms were created in DistillerSR. Data pertaining to study characteristics, risk of bias, and quality assessment were extracted independently and in duplicate (AT, CG and/or KH) . A calibration exercise for data extraction was conducted on the first three studies. Data was collected on study characteristics, including: general study characteristics, animal model characteristics (e.g. species, sex, model of disease or injury), MSC and EV isolation and characterization techniques, MSC or EV modifications, and dosage. Details for all data collected can be found in our registered PROSPERO protocol. We used the generally accepted size-based definitions of EV subtypes, i.e. exosomes or small EVs (30-150 nm in diameter) and microvesicles or large EVs (150-1000 nm in diameter) (Théry et al., 2018; Tieu et al., 2020) , to determine whether authors use of these terms was consistent with MISEV recommendations.

Since MSCs are a heterogeneous population of cells widely accessible from a variety of tissue sources, the International Society for Cell Therapy (ISCT) published guidelines to standardize MSC characterization. Studies were assessed for their adherence to the ISCT criteria including: (1) adherence to plastic in standard culture conditions, (2) positive and negative expression of specific surface antigens, and (3) multipotent differentiation potential. Furthermore, international guidelines for investigating EVs were published in 2018 entitled "Minimal Information for Studies of EVs" (MISEV 2018) (Théry et al., 2018) . Researchers are encouraged to characterize EVs by amount, two measures of single vesicle analysis, and at least three positive and one negative protein marker. These criteria were used to assess study adherence to EV characterization.

Outcomes were predetermined by consulting experts within the field of regenerative medicine and lung disease. Primary outcomes included histological lung injury scores for ALI, mean linear intercept (a measure of alveolarization) for BPD, and right ventricular systolic pressure for PAH. Secondary outcomes for ALI and BPD included protein concentration and neutrophil count in bronchoalveolar lavage fluid (measures of alveolar-capillary membrane permeability and inflammation, respectively).

For BPD and PAH, Fulton's index (a measure of right ventricular hypertrophy and indicator of pulmonary hypertension) was extracted as a secondary outcome. Tertiary outcomes, if reported, included measures of survival and adverse events of EV therapy. The corresponding authors of the individual studies included in our review were contacted to obtain relevant missing data.

Risk of bias was evaluated by two independent reviewers (AT, CG) using the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) risk of bias tool (Hooijmans et al., 2014) . The SYRCLE tool features 10 different parameters including randomization, blinding and outcome reporting, each of which was scored as having a low, high, or unclear risk of bias for each study. Quality of reporting was evaluated by two independent reviewers (AT, CG) using the NIH standards for transparency in reporting preclinical research. Each element in the NIH standards for transparency was scored as having been reported or not reported. Disagreements between reviewers were resolved through discussion (Fergusson et al., 2019a; NIH 2014) .

Extracted data on study characteristics, methodology and intervention characteristics are presented as frequencies, proportions and/or percentages. Studies may have used multiple techniques and interventions, either as separate experiments or in combination. Hence, the cumulative percentage of certain categories may be greater than 100%. Study outcomes were pooled using Comprehensive Meta-Analyst (version 3; BioStat Inc., USA) and represented by forest plots. Continuous outcome measures were expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs), which were calculated using a random effects inverse variance meta-analysis. Standardized mean difference was chosen due to the expected heterogeneity in the measurement techniques of outcomes. Dichotomous outcome measures were expressed as risk ratios (RRs) with 95% confidence intervals (CIs), which were calculated using a random effects meta-analysis based on the DerSimonian Laird model. We corrected for the multiple use of a single control group using the method described by Vesterinen et al (Vesterinen et al., 2014) . Statistical heterogeneity was assessed using the Cochrane I 2 test. Planned subgroup analyses included subgroups based on animal characteristics (e.g. sex, age, species), intervention characteristics (e.g. tissue source of MSCs, subtype of EVs, method of EV isolation), timing of treatment and respiratory disease modelled (e.g. ALI, BPD, PAH).

Our systematic searches yielded a total of 1167 records ( Figure 1 ). Following level 1 screening of titles and abstracts, 434 articles underwent level 2 full-text screening which resulted in a total of 52 studies included for our systematic review (Ahn et al., 2018; Aliotta et al., 2016 Aliotta et al., , 2017 Bandeira et al., 2018; Braun et al., 2018; Chaubey et al., 2018; Chen et al., 2014 Chen et al., , 2019 Chen et al., , 2020 Choi et al., 2014; Cruz et al., 2015; de Castro et al., 2017; Deng et al., 2020; Dinh et al., 2020; Fang et al., 2020a Fang et al., , 2020b Gao et al., 2020; Hao et al., 2019; Harrell et al., 2020; Huang et al., 2019; Khatri et al., 2018; Kim et al., 2020; Klinger et al., 2020; Lee et al., 2012; Lei et al., 2020; Li et al., 2015 Li et al., , 2019a Li et al., , 2020 Liu et al., 2018 Liu et al., , 2019a Liu et al., , 2019b Mansouri et al., 2019; Maremanda et al., 2019; Monroe et al., 2020; Monsel et al., 2015; Porzionato et al., 2019; Potter et al., 2018; Silva et al., 2019; Stone et al., 2017; Tang et al., 2017; Varkouhi et al., 2019; Wang et al., 2020; Willis et al., 2018 Willis et al., , 2020 Xu et al., 2019 Xu et al., , 2020 Yi et al., 2019; Zhang et al., 2020; Zhaorigetu et al., 2020; Zhu et al., 2014) . Our meta-analysis focussed on the three most frequently investigated diseases (ALI, BPD and PAH). Baseline characteristics of the included studies are reported in Table 1 . A majority of studies were conducted in the United States (N = 22; 42%) or China (N = 21; 42%) ( Figure S3 .1). The first paper examining MSC-EVs in a model of lung disease was published in 2012. Since then, there has been a marked growth in the number of preclinical animal studies investigating MSC-EVs with over 60% of studies (N = 32) published in 2019 and 2020 ( Figure S3 .1). A variety of lung conditions have been investigated including ALI (N = 23; 44%), PAH (N = 8; 15%), BPD (N = 7; 13%), asthma / allergic inflammation (N = 5; 10%), pulmonary fibrosis (N = 5; 10%), congenital diaphragmatic hernia (N = 2; 4%) and chronic obstructive pulmonary disease (N = 2; 4%). Most studies utilized either a mouse (N = 31; 60%) and/or rat (N = 21; 40%) model, with only one study applying a pig model (2%). Nearly half of the studies used only male animals (N = 24; 46%), with 8 studies using females only (15%), 2 studies using both sexes (4%), and 18 studies not reporting of the sex of their animals (35%). 

The animal source of MSCs used included human (N = 34; 65%), mouse (N = 11; 21%), rat (N = 8; 15%) and pig (N = 1; 2%) ( Figure S3 .2). MSCs were derived from a variety of tissue sources including bone marrow (N = 31; 60%), umbilical cord (N = 11; 21%), adipose tissue (N = 6; 12%), placenta (N = 3; 6%) and induced pluripotent stem cells (iPSCs) (N = 2; 4%) ( Figure S3 .2). Studies administered either xenogeneic EVs (N = 34; 65%) or allogeneic EVs (N = 20; 38%). Based on the ISCT guidelines, 30 studies (58%) met all three criteria for MSC characterization. In vitro trilineage differentiation and the positive/negative markers used in each study are described in Figure S3 .2. The most common techniques used for EV isolation were ultracentrifugation (N = 34; 65%), isolation kits (N = 7; 13%) and tangential flow filtration (N = 6; 12%) ( Figure S3 .3). EVs were characterized by quantification (N = 47; 90%), size distribution (N = 45; 87%), morphological analysis (N = 45; 87%) and/or surface marker expression (N = 41; 79%) in most studies (Figure S3 .3). Based on the MISEV 2018 guidelines, 10 studies (19%) adequately characterized their EV therapies. Importantly, 52% (N = 27) of studies did not report assessment of negative markers to demonstrate specific isolation of EVs. Regarding EV nomenclature, we assessed whether the terminology used was consistent with reported size distribution of EVs (e.g. small, large or both small/large EVs combined). Thirty-five (67%) studies utilized consistent terminology, whereas 8 studies (15%) used discordant terms and 9 studies (17%) did not provide size analysis. More details regarding EV isolation and characterization, including specific techniques and markers used, can be found in Figure S3 .3.

The two most common routes of administration for MSC-EV delivery included intravenous (N = 31; 60%) and intratracheal (N = 16; 31%) delivery ( Figure S3 .4). The units applied for dosing EVs varied considerably and included absolute protein amount (N = 23; 44%), particle number (N = 11; 21%) or amount of EVs released by a certain number of MSCs (N = 8; 15%), as well as EVs released over time or dosed by weight of animal ( Figure S3.4) . Most studies delivered a single dose of therapy (N = 35; 67%); studies with multiple administrations used a median value of 4 doses (ranging from 2-15 doses). EV modifications were conducted in 33 studies (63%) which included modifications before EV isolation (N = 17; 33%), modifications to EVs directly (N = 8; 15%) and co-treatments (N = 8; 15%). Lastly, dose-response and biodistribution analyses were examined in 8 (15%) and 7 (13%) studies, respectively ( Figure S3 .4).

Method of ALI induction included intratracheal endotoxin (e.g. lipopolysaccharide; N = 8), intratracheal E. Coli (N = 3), ischemia-reperfusion injury (N = 2), bleomycin injection (N = 2), smoke inhalation (N = 1), radiation (N = 1), viral induction (N = 1), shock (N = 1), phosgene (N = 1), burn (N = 1), trauma (N = 1) or intestinal ischemia-reperfusion (N = 1). Histological lung injury was reported in 7 studies investigating preclinical ALI. All 7 studies demonstrated a significant reduction in lung injury from MSC-EV therapy (pooled analysis, SMD -4.33, 95%CI -5.73 to -2.92, I 2 = 74%) (Figure 2 ). Subgroup analyses demonstrated that small EVs consistently result in a significant attenuation of lung injury whereas the efficacy of large EVs is highly variable and similar to control treatments from pooled analysis (Figure 3 ). Studies that isolated EVs by ultracentrifugation did F I G U R E  Subgroup analysis for all included studies of acute lung injury that reported the primary outcome of lung injury score. Each row represents pooled estimate data from studies within that subgroup. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. I 2 value represents the statistical heterogeneity within each subgroup. Effect sizes < 0 favours EV treatment and > 0 favours control. The 'Overall Efficacy' is a pooled estimate effect of MSC-EVs on lung injury score from all studies combined not demonstrate a difference in effect size as compared to the single study that utilized an isolation kit ( Figure 3) . Lastly, MSC-EVs may demonstrate greater benefits (P = 0.004) to attenuate lung injury in female rodents as compared to males, however only one study used female animals (Figure 3) . No difference in effect size was observed between MSC tissue source (bone marrow vs. umbilical cord), species source of MSCs, immunocompatibility (allogeneic vs. xenogeneic), timing of treatment, route of administration or animal model (Figure 3 ). Changes to alveolar-capillary barrier permeability measured by bronchoalveolar lavage fluid (BALF) protein concentration were reported in 28 studies. Overall, MSC-EV administration was associated with a significant attenuation of lung permeability (SMD -2.43, 95%CI -3.05 to -1.82, I 2 = 83%) (Figure 4) . From subgroup analysis, lung permeability was reduced to a greater extent (P < 0.001) by delivery of small EVs or both small/large as compared to large EVs alone ( Figure 5 ). Allogeneic administration of MSC-EVs also showed a greater reduction in lung permeability compared to xenogeneic delivery (P = 0.001). Sex (P = 0.009) and species (P = 0.03) may be associated with greater EV efficacy as female animals and rat models demonstrated better outcomes ( Figure 5) . Lastly, the single study that used an isolation kit displayed a greater improvement (P < 0.001) to lung permeability as compared to studies that utilized ultracentrifugation. Similar to lung injury score, no difference in effect size was observed when considering MSC tissue source, route of administration or timing of treatment.

Other secondary outcomes considered for ALI studies included mortality (RR 0.39, 95%CI 0.22 to 0.68, I 2 = 14%) (Figure S4 .1) and inflammatory response as measured by neutrophil infiltration in BALF (SMD -1.42, 95%CI -1.83 to -1.02, I 2 = 66%) ( Figure S4.2) , both of which were significantly improved by MSC-EV therapy. Lastly, a dose-response analysis F I G U R E  Meta-analysis for all included studies of acute lung injury and bronchopulmonary dysplasia that reported the secondary outcome of alveolar capillary permeability. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. Effect sizes < 0 favours EV treatment and > 0 favours control. Subscript denotes a separate study or article that was published within the same year. The 'Overall Efficacy' represents a pooled estimate of MSC-EV effect on lung vascular permeability from all studies combined. I 2 value represents the statistical heterogeneity was conducted for studies administering EVs by protein amount and reporting lung vascular permeability as an outcome. Despite many studies delivering similar doses, the effect size varied considerably and was not correlated to dose (P = 0.311) ( Figure S4 .3).

All animal models of BPD were induced by housing new-born mice or rats under hyperoxia conditions, ranging from 60-95% oxygen. Alveolarization was reported in 11 studies from 7 different articles and pooled analysis demonstrated marked improvements from MSC-EV administration (SMD -1.45, 95%CI -2.08 to -0.82, I 2 = 63%) ( Figure 6 ). Similar to ALI, subgroup analysis indicated that small EVs consistently improve alveolarization, whereas the combination of small/large EVs were highly variable and not statistically different as compared to control (Figure 7) . One study that isolated EVs by TFF did not exhibit any benefits from EVs. However, when TFF was combined with density gradient ultracentrifugation or ultracentrifugation was used alone, MSC-EVs significantly improved lung alveolarization (P = 0.008) (Figure 7) . Immunocompatibility (allogeneic, P = 0.045), route of administration (intraperitoneal, P = 0.040) and timing of treatment (concurrent, P = 0.044) may result in differential effects, whereas no differences in efficacy was observed when comparing tissue source of MSCs or animal species.

One study evaluated the survival benefits of MSC-EVs in experimental BPD; however, mortality was shown to be unaltered as compared to control (RR 0.86, 95%CI 0.41 to 1.80) ( Figure S4 .1). Other secondary outcomes of experimental BPD that were assessed include alveolar permeability (SMD -1.80, 95%CI -3.18 to -0.41, I 2 = 67%) ( Figure 4) and lung inflammation as measured by BALF neutrophil (SMD -2.48, 95%CI -3.41 to -1.75, I 2 = 66%) ( Figure S4.2) , both of which demonstrated significant improvements from MSC-EV delivery. Furthermore, MSC-EV delivery resulted in marked reductions to both Fulton's Index (measure F I G U R E  Subgroup analysis for all included studies of acute lung injury that reported the secondary outcome of alveolar capillary permeability. Each row represents pooled estimate data from studies within that subgroup. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. I 2 value represents the statistical heterogeneity within each subgroup. Effect sizes < 0 favours EV treatment and > 0 favours control. The 'Overall Efficacy' is a pooled estimate effect of MSC-EVs on lung vascular permeability from all studies of acute lung injury combined of right ventricular hypertrophy; SMD -0.99, 95%CI -1.49 to -0.49, I 2 = 0%) ( Figure S4 .4) and RVSP (SMD -1.20, 95%CI -2.07 to -0.34, I 2 = 0%) ( Figure S4 .5).

Method for PAH induction included monocrotaline injection (N = 5), chronic hypoxia(N = 2), or the combination of semaxanib (SU5416) and chronic hypoxia in rats (N = 2). Ten distinct studies from 5 articles reported RVSP, each of which demonstrated a significant reduction after MSC-EV administration (pooled analysis, SMD -4.16, 95%CI -5.68 to -2.64, I 2 = 84%) (Figure 8 ). Exploratory subgroup analysis showed allogeneic MSC-EVs improved RVSP to a significantly greater extent than xenogeneic administration (P < 0.001) (Figure 9 ). Interestingly, in the single report of EVs isolated by combining TFF and size exclusion chromatography, EVs were less efficacious (P < 0.001) as compared to ultracentrifugation or ultracentrifugation/chromatography combined (Figure 9 ). Studies that did not report sex showed a significantly greater reduction in RVSP as compared to maleonly studies (P < 0.001). Despite the well-known sex dependency of PAH, no preclinical study explored MSC-EV therapy in female animals. Unlike ALI or BPD, EV subtype did not demonstrate variable effects to RVSP. No differences in EV efficacy were observed when comparing MSC tissue source or timing of treatment ( Figure 9) . Lastly, 17 studies reported the secondary outcome F I G U R E  Meta-analysis for all included studies of bronchopulmonary dysplasia that reported the primary outcome of lung alveolarization. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. Effect sizes < 0 favours EV treatment and > 0 favours control. Subscript denotes a separate study or article that was published within the same year. The 'Overall Efficacy' represents a pooled estimate of MSC-EV effect on alveolarization from all studies combined. I 2 value represents the statistical heterogeneity of Fulton's Index. In these studies, MSC-EV administration led to a significant reduction in right ventricular hypertrophy (SMD -2.80, 95%CI -3.68 to -1.91, I 2 = 78%) ( Figure S4 .4).

3.6.1 Asthma / allergic airway inflammation (N = 5 studies) Disease was induced by intraperitoneal delivery of ovalbumin (N = 3) (De Castro et al., 2017; Fang et al., 2020a; Kim et al., 2020) , Aspergillus fumigatus hyphal extract (N = 1) (Cruz et al., 2015) , or IL-33 (N = 1) (Fang et al., 2020b) . MSC-EVs were administered by intravenous injection in 4 studies, with one study using intranasal delivery for more localized lung distribution. Four studies assessed in vivo outcomes, all of which reported a significant reduction to BALF neutrophils, eosinophils and proinflammatory cytokines from MSC-EV delivery. Three studies reported a marked attenuation in lung inflammation score. One study showed improvements to lung mechanics, and another demonstrated a reduction in lung hyperresponsiveness to allergens (e.g. Aspergillus hyphal). Lastly, one study assessed differential gene expression in lung tissues post-EV administration and found the most upregulated genes were those related to antioxidation (Pon1), mitochondrial function (Bex2) and lung epithelium protection (Scgb1c1). Of note, the inhibition of miR-146a abolished the therapeutic efficacy of MSC-EVs, thereby illustrating its critical role within EVs for immunomodulation.

3.6.2 Pulmonary fibrosis (N = 5 studies) Fibrosis was induced by intratracheal silica (N = 2) (Bandeira et al., 2018; Choi et al., 2014) , bleomycin (N = 2) (Dinh et al., 2020; Mansouri et al., 2019) , or fine particulate matter (N = 1) (Gao et al., 2020) . All studies delivered MSC-EVs as a rescue treatment which led to reduced lung collagen content in three studies, one of which was still significantly elevated as compared to control. In the other two studies, MSC-EV treated animals did not attenuate collagen deposition, whereas MSCs themselves or lung spheroid cell exosomes led to marked improvements. The effect of MSC-EVs on BALF macrophage expression was variable. Two studies reported no changes in number of lung macrophages, whereas one study observed a rescued expression of anti-inflammatory macrophages. Most studies demonstrated reduced expression of pro-inflammatory cytokines including IL-1β, TGFβ1 and TNFα. Lastly, one study found that transplantation of bone marrow derived monocytes preconditioned with MSC-EVs attenuated both pulmonary fibrosis and lung inflammation.

F I G U R E  Subgroup analysis for all included studies of bronchopulmonary dysplasia that reported the primary outcome of lung alveolarization. Each row represents pooled estimate data from studies within that subgroup. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. I 2 value represents the statistical heterogeneity within each subgroup. Effect sizes < 0 favours EV treatment and > 0 favours control. The 'Overall Efficacy' is a pooled estimate effect of MSC-EVs on alveolarization from all studies combined F I G U R E  Meta-analysis for all included studies of pulmonary arterial hypertension that reported the primary outcome of right ventricular systolic pressure. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. Effect sizes < 0 favours EV treatment and > 0 favours control. Subscript denotes a separate study or article that was published within the same year. The 'Overall Efficacy' represents a pooled estimate of MSC-EV effect on right ventricular systolic pressure from all studies combined. I 2 value represents the statistical heterogeneity F I G U R E  Subgroup analysis for all included studies of pulmonary arterial hypertension that reported the primary outcome of right ventricular systolic pressure. Each row represents pooled estimate data from studies within that subgroup. Data is presented as a forest plot with standardized mean difference and 95% confidence intervals. I 2 value represents the statistical heterogeneity within each subgroup. Effect sizes < 0 favours EV treatment and > 0 favours control. The 'Overall Efficacy' is a pooled estimate effect of MSC-EVs on right ventricular systolic pressure from all studies combined 3.6.3 Chronic obstructive pulmonary disease (COPD)

Two articles (4%) studied the effects of MSC-EVs in a cigarette smoke induced mouse model of COPD Maremanda et al., 2019) . In one study, the combination of MSCs and exosomes were more effective than either treatment alone to reduce BALF cell count and cytokine levels (Maremanda et al., 2019) . The mechanism of action was found to be recovery of mitochondrial transfer and mitochondrial fusion gene expression. The second study of COPD found intraperitoneal delivery of MSC-EVs resulted in marked reductions to plasma pro-inflammatory cytokines, histological lung injury and lung influx of inflammatory immune cells .

All 52 lung articles were assessed for their completeness of reporting study design domains based on the NIH Principles and Guidelines for Reporting in Preclinical Research (NIH 2014). These guidelines identify parameters that should be included in preclinical publications to enhance scientific rigor, reproducibility and transparency. No articles used established reporting guidelines (e.g. Animal Research: Reporting In Vivo Experiments, ARRIVE) ( Figure S6 ). Findings were substantiated under a range of conditions (e.g. different dosages, routes of administration, modifications) in 31 studies (60%). Forty studies (77%) stated Nvalues for at least one in vivo outcome and 31 studies (60%) for all outcomes. A priori sample size determination was described in seven studies (13%); however, all seven studies had inadequate information necessary to reproduce calculations. The total number of animals used in all experiments was reported in 17 studies (33%) ( Figure S6) . A primary outcome was not explicitly stated in any of the 52 studies ( Figure S6 ). The number of measurements per subject was described for at least one outcome in 30 studies (58%), two of which reported the number of replicates in all findings. Randomization of experimental groups was mentioned in less than half of the articles (N = 24); however, the method of randomization was not described in any article. No studies reported blinding of the personnel conducting experiments. Blinding of data analysis was described for all outcomes in two studies (4%) and some outcomes in 16 studies (31%), with no blinding of outcome assessment mentioned for 33 studies (66%). Lastly, the NIH recommends reporting the criteria for data exclusion to minimize selection bias. Seven studies (13%) provided reasoning for data omission, which included excluding animals with heart rates < 300 beats per minute for hemodynamic measurements (Willis et al., 2018) , low expression of genes in RNA sequencing , or statistical outliers (Varkouhi et al., 2019) . Forty-five studies (87%) did not provide any criteria for data exclusion ( Figure S6 ).

A majority of studies were deemed as having an 'unclear' risk of bias across most domains ( Figure 10 ). Although 24 studies (46%) reported that animals were randomized to experimental groups, no studies provided details regarding method of randomization (i.e. to reduce selection bias) which is essential to assess adequate random sequence generation. Thirty-two studies (62%) displayed a low risk for reporting baseline characteristics (i.e. to reduce selection bias). However, the risk of bias was unclear across all studies for the domains of allocation concealment (i.e. selection bias), random housing (i.e. selection bias), blinding of personnel (i.e. performance bias) and selective outcome reporting (i.e. reporting bias). Seventeen studies reported blinded assessments (i.e. detection bias) for some outcomes (e.g. histological/pathological injury) and 2 studies were blinded for all outcomes. Incomplete outcome data (i.e. attrition bias) was assessed as whether the N-value was consistent between the methods and results sections. Fourteen studies (27%) exhibited low risk, 25 studies (48%) had unclear risk and 13 studies (25%) were deemed high risk. Lastly, other potential sources of bias considered included source of funding, sample size calculation and conflict of interests. Eleven studies (21%) had a high risk in at least one of these additional categories. (Figure 10 ).

Our systematic review provides a comprehensive synthesis of the preclinical efficacy, methodology, study design and preclinical reporting of MSC-EV studies of acute and chronic respiratory diseases. Pooled estimates from meta-analyses indicate that MSC-EV administration significantly improves primary outcomes in ALI (i.e. lung injury score), BPD (i.e. alveolarization) and PAH (i.e. right ventricular systolic pressure). With the exception of mortality for BPD, MSC-EVs were also markedly effective at improving secondary outcomes including survival (ALI), lung vascular permeability (ALI and BPD), BALF neutrophil count (ALI and BPD), RVSP (BPD) and Fulton's Index (BPD and PAH). These findings demonstrate the therapeutic efficacy of MSC-EVs to treat both acute and chronic lung diseases.

Our previous systematic analysis of all animal studies investigating MSC-EVs found high heterogeneity in how EVs are being isolated and characterized (Tieu et al., 2020) . Moreover, there were significant inconsistencies in nomenclature being used to describe EV therapy and variability in interventional characteristics including tissue source of MSCs and treatment regimen. After updating our search and limiting our review to publications related to lung disorders, we still observed similar heterogeneity. When assessing whether groups were characterizing their MSCs and EVs according to international guidelines (e.g. ISCT criteria and MISEV 2018) (Dominici et al., 2006; Théry et al., 2018) , we found that 58% and 19% of studies met the recommendations, respectively. This is a significant increase from our previous reports of only 2% adherence to MISEV 2018 (Tieu et al., 2020) which highlights the impact of these guidelines for improving EV characterization. EV nomenclature remains inconsistent despite the suggestions from MISEV 2018 to describe EV therapies by physical parameters (e.g. small EVs 30-150 nm, large EVs 150-1000 nm). Based on size alone, we found that over 30% of studies are using discordant terminology. This finding may be problematic for two reasons: (1) inconsistent terms will hinder between study comparisons of different EV populations, and (2) our finding likely is an underestimate as we only considered size and did not include analysis of EV cellular origin (e.g. exosomes originate as intraluminal vesicles within late endosomes). Greater standardization in reporting of size and applying accurate terminology in the EV field can help identify specific EV populations that serve as a more effective therapeutic product.

Given the many variables involved in developing an MSC-EV therapy, we conducted exploratory subgroup analyses to determine if specific EV parameters may be associated with improved efficacy. Across studies of ALI, BPD and PAH, the different tissue sources of MSCs (e.g. bone marrow, umbilical cord, placenta) and routes of administration (e.g. intravenous, intraperitoneal, intratracheal) were equally efficacious, despite beliefs that intratracheal delivery may allow for greater lung distribution. Moreover, umbilical cord tissue is known to be more efficient in producing EVs with potentially less variability from donor demographics (e.g. age, sex, comorbidities) and serves as a non-invasive, abundant source for MSCs given its designation as biohazardous waste (Curley et al., 2017; Fong et al., 2012; Hua et al., 2014) . Hence, the similar efficacy and ease in collection of umbilical cord tissue suggests some potential advantages when considering clinical translation. EVs isolated by TFF appeared to be less effective than those enriched by ultracentrifugation for preclinical BPD and PAH (no studies used TFF in ALI). However, these findings were from only two studies that utilized TFF and more direct comparisons of TFF and ultracentrifugation are warranted to establish the relative in vivo efficacy of EVs, especially given TFF's greater efficiency in EV yield and potential for clinical scaleup (Haraszti et al., 2018) . Lastly, we conducted subgroup analysis by EV subtype/size to investigate whether distinct EV populations may exhibit variable outcomes. Small EVs or the combination of small/large EVs were found to be more F I G U R E   Risk of bias assessment in accordance with the SYRCLE tool. Yellow represents unclear, green represents low risk of bias and red represents high risk of bias. Light yellow represents a study that reported randomization or sample size calculations, but did not provide detailed methodology on how these parameters were achieved. Light green under 'blinding of outcome' represents studies that blinded some outcomes, whereas dark green represents blinding of all outcomes consistently beneficial as compared to large EVs in ALI and BPD (no studies used large EVs in PAH). Moreover, small EVs led to a significant improvement in lung vascular permeability as compared to large EVs. These results may indicate that there are differential effects between small and large EVs, which may not be dependent on acuity/chronicity of the disease state.

Our study had limitations which warrant discussion. Firstly, the findings from subgroup analyses should be considered exploratory. We show that specific EV characteristics are associated with greater efficacy in these investigations. However, some subgroup categories were limited by the number of available studies and/or the sample size. Hence, updated analyses when more studies are published will be required to generate definitive conclusions. Our findings identify the need for robust data from head-to-head comparisons of EV methodology and/or subtypes to identify the most effective approaches for clinical translation. Next, data generated from studies with a low risk of bias may serve as a more accurate indicator for the efficacy of MSC-EVs. Unfortunately, most studies included in our analysis demonstrated an "unclear" risk across a majority of design parameters, which is commonly observed in many fields of preclinical in vivo research (Avey et al., 2016; Bailey et al., 2021a Bailey et al., , 2021b Begley & Ioannidis, 2015; Fergusson et al., 2019a Fergusson et al., , 2019b . Future analyses will provide greater insights once researchers and journals adopt more complete reporting of preclinical study design (Collins & Tabak, 2014; Henderson et al., 2013; Landis et al., 2012) . Lastly, although no adverse events were reported, none of the included studies conducted formal experiments to investigate MSC-EV safety.

Although MSC-EV therapy demonstrates great promise, several questions still need to be answered to advance the field. We found dose-response and biodistribution studies to be infrequently conducted in respiratory diseases, which is also the case for the MSC-EV field as a whole (Tieu et al., 2020) . These experiments are urgently needed to better understand the optimal approach for dosing EVs before attempting clinical translation. Moreover, there are no standardized guidelines on how EV dose should be measured and reported (e.g. protein, particle or RNA amount). We now know that MSC-EVs contain many bioactive factors including mRNas, microRNAs and proteins that modulate critical cell processes ranging from inflammation to apoptosis to angiogenesis (Tieu et al., 2020) . Although many studies show the importance of specific molecules by inhibiting their expression, few have attempted to compare whether overexpressing one bioactive factor is more important than others. Lastly, quality of reporting and potential risk of bias in study design is consistently unclear in preclinical EV research. Greater rigor and transparent detailing of experimental parameters including randomization, blinding, and sample size estimates will generate more robust evidence for EV efficacy to guide clinical translation.

AT is an MD/PhD candidate supported as a Vanier Scholar with the Canadian Institutes of Health Research (CIHR), a Canadian Vascular Network Scholar and an Audrey J Boyce MD/PhD Fellow. MML is supported by the Ottawa Hospital Anesthesia Alternate Funds Association and holds a University of Ottawa Junior Research Chair in Innovative Translational Research. The authors thank Risa Shorr, librarian and information specialist within the Ottawa Hospital Research Institute who designed the search strategy for this systematic review.

Duncan J. Stewart is an advisor to Northern Therapeutics (Montreal, QC, Canada). The remaining authors have no competing interests to declare.

Bone marrow endothelial progenitor cells are the cellular mediators of pulmonary hypertension in the murine monocrotaline injury model

Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice

The devil is in the details: Incomplete reporting in preclinical animal research

MSC-Derived Extracellular Vesicles to Heal Diabetic Wounds: a Systematic Review and Meta-Analysis of Preclinical Animal Studies

Mesenchymal Stromal Cell-derived Extracellular Vesicles in Preclinical Animal Models of Tumor Growth: Systematic Review and Meta-analysis

Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis

Reproducibility in science: Improving the standard for basic and preclinical research

Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6

Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats

Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs

Microvesicles derived from human Wharton's Jelly mesenchymal stem cells ameliorate acute lung injury partly mediated by hepatocyte growth factor

Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury via delivery of miR-100

Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell

Policy: NIH plans to enhance reproducibility

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles

Systematic review and meta-analysis methodology

Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice

Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli-induced acute respiratory distress syndrome

Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma

Bone marrow mesenchymal stem cell-derived exosomes attenuate LPS-induced ARDS by modulating macrophage polarization through inhibiting glycolysis in macrophages

Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis

Minimal criteria for defining multipotent mesenchymal stromal cells

Small extracellular vesicles derived from human MSCs prevent allergic airway inflammation via immunomodulation on pulmonary macrophages

Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p

Assessing the completeness of reporting in preclinical oncolytic virus therapy studies

Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo

Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities

Extracellular vesicles derived from adipose mesenchymal stem cells alleviate PM2. 5-Induced lung injury and pulmonary fibrosis

Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells

Effects of mesenchymal stromal cell-derived extracellular vesicles in lung diseases: Current status and future perspectives

Meta-analysis and the science of research synthesis

Mesenchymal stem cell-derived extracellular vesicles decrease lung injury in mice

Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yield and improved activity

Molecular and cellular mechanisms responsible for beneficial effects of mesenchymal stem cell-derived product "Exo-d-MAPPS" in attenuation of chronic airway inflammation

Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells, , 1605

Threats to validity in the design and conduct of preclinical efficacy studies: A systematic review of guidelines for in vivo animal experiments

Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension

Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension

SYRCLE's risk of bias tool for animal studies

Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: Proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow

Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury

Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Screening and functional pathway analysis of pulmonary genes associated with suppression of allergic airway inflammation by adipose stem cell-derived extracellular vesicles

Mesenchymal stem cell extracellular vesicles reverse sugen/hypoxia pulmonary hypertension in rats

Multipotent mesenchymal stromal cells and the innate immune system

Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension

Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury

Mesenchymal Stem Cells Derived Extracellular Vesicles Attenuate Radiation-Induced Lung Injury via miRNA-214-3p

Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p

Ischemic preconditioning potentiates the protective effect of mesenchymal stem cells on endotoxin-induced acute lung injury in mice through secretion of exosome

Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats

Intratracheal transplantation of amnion-derived mesenchymal stem cells ameliorates hyperoxia-induced neonatal hyperoxic lung injury via aminoacyl-peptide hydrolase

Exosomes released by bone marrow mesenchymal stem cells attenuate lung injury induced by intestinal ischemia reperfusion via the TLR4/NF-kappaB pathway

Exosomal miR-451 from human umbilical cord mesenchymal stem cells attenuates burn-induced acute lung injury

Mesenchymal stem cell-derived microvesicles alleviate pulmonary arterial hypertension by regulating renin-angiotensin system

Challenges and controversies in human mesenchymal stem cell therapy

Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes

Protective role of mesenchymal stem cells and mesenchymal stem cell-derived exosomes in cigarette smoke-induced mitochondrial dysfunction in mice

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial

PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement

Extracellular vesicles influence the pulmonary arterial extracellular matrix in congenital diaphragmatic hernia

Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice

Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases

New evidence pyramid

Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia

Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma

Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: A scoping review of the evidence

Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord

Systematic reviews and meta-analysis of preclinical studies: Why perform them and how to appraise them critically

Mesenchymal stromal cells are more effective than their extracellular vesicles at reducing lung injury regardless of acute respiratory distress syndrome etiology

Prevalence and attributable health burden of chronic respiratory diseases

Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death

Mesenchymal stem cell microvesicles attenuate acute lung injury in mice partly mediated by Ang-1 mRNA

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

An analysis of mesenchymal stem cell-derived extracellular vesicles for preclinical use

Extracellular vesicles from interferon-γ-primed human umbilical cord mesenchymal stromal cells reduce Escherichia coli-induced acute lung injury in rats

Meta-analysis of data from animal studies: A practical guide

Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 

Mesenchymal stem cell-derived extracellular vesicles alleviate acute lung injury via transfer of miR-27a-3p

Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation

Mesenchymal stromal cell-derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia-induced lung injury

World Heath Organization (WHO)

Therapeutic use of extracellular vesicles for acute and chronic lung disease

BMSC-derived exosomes alleviate smoke inhalation lung injury through blockade of the HMGB1/NF-κB pathway

Mesenchymal stem cell-derived exosomes attenuate phosgene-induced acute lung injury in rats

Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3

Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling

Extracellular vesicles attenuate nitrofen-mediated human pulmonary artery endothelial dysfunction: Implications for congenital diaphragmatic hernia

Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice